Results from this study revealed that following transplantation, both pineal and adrenal medullary transplants significantly lowered immobility scores. In contrast to the monoamine transplant groups, the mean immobility scores for the sciatic nerve group and the nonimplanted group were not reduced from FST immobility scores prior to transplantation.
Biochemical results showed that serotonin levels and norepinephrine levels, in the pineal implanted group and adrenal medullary implanted group, respectively, were significantly higher than both the sciatic implanted and the non-implanted groups.
In conclusion, these studies suggest that monoaminergic neural transplants can provide a local source of monoamines for antidepressive action. The ability of monoaminergic grafts to alleviate depression in two different animal models is a promising finding that adds credence to the possibility of monoaminergic neural transplants providing a new approach to the treatment of clinical depression.
